Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report
BackgroundHalf of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approv...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1043244/full |
| _version_ | 1797851253410103296 |
|---|---|
| author | Jingyi Wang Xiaoqing Li Juan Zhou Dan Qiu Mengyao Zhang Lan Sun Shengwen Calvin Li Shengwen Calvin Li |
| author_facet | Jingyi Wang Xiaoqing Li Juan Zhou Dan Qiu Mengyao Zhang Lan Sun Shengwen Calvin Li Shengwen Calvin Li |
| author_sort | Jingyi Wang |
| collection | DOAJ |
| description | BackgroundHalf of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approved for the standard third-line treatment for NSCLC in China. Herein we report an elderly NSCLC patient without any driver gene mutations who was undergoing anlotinib as a front-line treatment and who achieved long-term survival.Case summaryThe 77-year-old male patient was admitted to the hospital for chest tightness after engaging in physical activity for a week. The patient has been diagnosed with stage IIIB driver gene-negative squamous cell lung carcinoma. After that, he was treated with anlotinib for 2 years and 10 months from the first diagnosis until the last disease progression. Briefly, anlotinib combined with platinum-based chemotherapy was performed as the first-line therapy over six cycles. After 6 more cycles of anlotinib monotherapy maintenance, disease progression occurred. Then, anlotinib combined with tegafur was administered as a salvage treatment, and the disease was controlled again. After 29 cycles of anlotinib combined with tegafur regimens, the disease progressed finally. The patient achieved a total of 34 months of progression-free survival after anlotinib was used as the front-line treatment. He is still alive with a good performance status now (performance status score: 1).ConclusionThis patient achieved long-term survival using anlotinib as a front-line regimen combined with chemotherapy. |
| first_indexed | 2024-04-09T19:14:53Z |
| format | Article |
| id | doaj.art-a17dae1199f44e21b98202c868c75f65 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T19:14:53Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a17dae1199f44e21b98202c868c75f652023-04-06T06:29:17ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-04-011310.3389/fonc.2023.10432441043244Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case reportJingyi Wang0Xiaoqing Li1Juan Zhou2Dan Qiu3Mengyao Zhang4Lan Sun5Shengwen Calvin Li6Shengwen Calvin Li7Department of Oncology, Bishan Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Oncology, Bishan Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Oncology, Bishan Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Oncology, Bishan Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Oncology, Bishan Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Oncology, Bishan Hospital of Chongqing Medical University, Chongqing, ChinaNeuro-Oncology and Stem Cell Research Laboratory, Center for Neuroscience Research, CHOC Children’s Research Institute, Children’s Hospital of Orange County (CHOC), Orange, CA, United StatesDepartment of Neurology, University of California-Irvine School of Medicine, Orange, CA, United StatesBackgroundHalf of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approved for the standard third-line treatment for NSCLC in China. Herein we report an elderly NSCLC patient without any driver gene mutations who was undergoing anlotinib as a front-line treatment and who achieved long-term survival.Case summaryThe 77-year-old male patient was admitted to the hospital for chest tightness after engaging in physical activity for a week. The patient has been diagnosed with stage IIIB driver gene-negative squamous cell lung carcinoma. After that, he was treated with anlotinib for 2 years and 10 months from the first diagnosis until the last disease progression. Briefly, anlotinib combined with platinum-based chemotherapy was performed as the first-line therapy over six cycles. After 6 more cycles of anlotinib monotherapy maintenance, disease progression occurred. Then, anlotinib combined with tegafur was administered as a salvage treatment, and the disease was controlled again. After 29 cycles of anlotinib combined with tegafur regimens, the disease progressed finally. The patient achieved a total of 34 months of progression-free survival after anlotinib was used as the front-line treatment. He is still alive with a good performance status now (performance status score: 1).ConclusionThis patient achieved long-term survival using anlotinib as a front-line regimen combined with chemotherapy.https://www.frontiersin.org/articles/10.3389/fonc.2023.1043244/fullnon-small cell lung canceranti-angiogenesis therapyfront-line treatmentelderly patientscase reportAnlotinib hydrochloride |
| spellingShingle | Jingyi Wang Xiaoqing Li Juan Zhou Dan Qiu Mengyao Zhang Lan Sun Shengwen Calvin Li Shengwen Calvin Li Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report Frontiers in Oncology non-small cell lung cancer anti-angiogenesis therapy front-line treatment elderly patients case report Anlotinib hydrochloride |
| title | Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report |
| title_full | Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report |
| title_fullStr | Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report |
| title_full_unstemmed | Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report |
| title_short | Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report |
| title_sort | long term survival with anlotinib as a front line treatment in an elderly nsclc patient a case report |
| topic | non-small cell lung cancer anti-angiogenesis therapy front-line treatment elderly patients case report Anlotinib hydrochloride |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1043244/full |
| work_keys_str_mv | AT jingyiwang longtermsurvivalwithanlotinibasafrontlinetreatmentinanelderlynsclcpatientacasereport AT xiaoqingli longtermsurvivalwithanlotinibasafrontlinetreatmentinanelderlynsclcpatientacasereport AT juanzhou longtermsurvivalwithanlotinibasafrontlinetreatmentinanelderlynsclcpatientacasereport AT danqiu longtermsurvivalwithanlotinibasafrontlinetreatmentinanelderlynsclcpatientacasereport AT mengyaozhang longtermsurvivalwithanlotinibasafrontlinetreatmentinanelderlynsclcpatientacasereport AT lansun longtermsurvivalwithanlotinibasafrontlinetreatmentinanelderlynsclcpatientacasereport AT shengwencalvinli longtermsurvivalwithanlotinibasafrontlinetreatmentinanelderlynsclcpatientacasereport AT shengwencalvinli longtermsurvivalwithanlotinibasafrontlinetreatmentinanelderlynsclcpatientacasereport |